X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SUVEN LIFE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SUVEN LIFE FRESENIUS KABI ONCO./
SUVEN LIFE
 
P/E (TTM) x 22.1 20.2 109.8% View Chart
P/BV x 3.1 4.4 70.7% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   SUVEN LIFE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SUVEN LIFE
Mar-18
FRESENIUS KABI ONCO./
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs176251 70.2%   
Low Rs79155 50.6%   
Sales per share (Unadj.) Rs37.749.1 76.7%  
Earnings per share (Unadj.) Rs5.19.7 52.4%  
Cash flow per share (Unadj.) Rs6.711.4 59.0%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs42.560.3 70.6%  
Shares outstanding (eoy) m158.23127.28 124.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.1 81.8%   
Avg P/E ratio x25.020.9 119.7%  
P/CF ratio (eoy) x18.917.8 106.3%  
Price / Book Value ratio x3.03.4 88.9%  
Dividend payout %015.4 0.0%   
Avg Mkt Cap Rs m20,13525,825 78.0%   
No. of employees `0001.21.1 107.5%   
Total wages/salary Rs m703613 114.8%   
Avg. sales/employee Rs Th5,176.25,832.6 88.7%   
Avg. wages/employee Rs Th610.4571.5 106.8%   
Avg. net profit/employee Rs Th699.61,153.8 60.6%   
INCOME DATA
Net Sales Rs m5,9636,253 95.4%  
Other income Rs m18233 7.7%   
Total revenues Rs m5,9816,485 92.2%   
Gross profit Rs m1,4301,982 72.2%  
Depreciation Rs m258213 121.0%   
Interest Rs m-2646 -56.2%   
Profit before tax Rs m1,2161,955 62.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342718 47.6%   
Profit after tax Rs m8061,237 65.2%  
Gross profit margin %24.031.7 75.7%  
Effective tax rate %28.136.7 76.6%   
Net profit margin %13.519.8 68.3%  
BALANCE SHEET DATA
Current assets Rs m5,1025,622 90.7%   
Current liabilities Rs m2,3851,168 204.3%   
Net working cap to sales %45.671.2 63.9%  
Current ratio x2.14.8 44.4%  
Inventory Days Days15081 184.3%  
Debtors Days Days11336 315.4%  
Net fixed assets Rs m5,1483,325 154.8%   
Share capital Rs m158127 124.3%   
"Free" reserves Rs m6,5567,547 86.9%   
Net worth Rs m6,7327,674 87.7%   
Long term debt Rs m95214 6,850.4%   
Total assets Rs m10,3889,135 113.7%  
Interest coverage x-45.843.2 -105.9%   
Debt to equity ratio x0.10 7,809.3%  
Sales to assets ratio x0.60.7 83.9%   
Return on assets %7.514.0 53.5%  
Return on equity %12.016.1 74.3%  
Return on capital %14.626.0 56.1%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2985,066 104.6%   
Fx outflow Rs m1,7722,001 88.6%   
Net fx Rs m3,5253,065 115.0%   
CASH FLOW
From Operations Rs m1,274699 182.2%  
From Investments Rs m-1,204-6 19,741.0%  
From Financial Activity Rs m-196-577 34.0%  
Net Cashflow Rs m-126116 -108.6%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 9.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   42,599 37,287 114.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS